Precision Life Sciences Group — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Precision Lifesciences Group is a private, pre-revenue biotech firm founded in 2016, specializing in novel cell therapies for oncology. Its core technology is the Stem-to-T-Cell platform, an early-stage approach designed to engineer a patient's own stem cells to produce a continuous, controlled supply of tumor-specific killer T cells, potentially offering advantages in safety and durability over existing therapies like CAR-T. The company also holds three clinical-stage dendritic cell vaccine assets (ICT-107, ICT-121, ICT-140) for which it is seeking development partners. With operations in Boston and Nashville, the company is positioned in the competitive but high-potential field of cancer immunotherapy.

Oncology

Technology Platform

Two complementary platforms: 1) A dendritic cell-based immunotherapy platform that educates the patient's immune system ex vivo, and 2) A novel Stem-to-T-Cell platform that engineers a patient's hematopoietic stem cells to serve as a long-term, in vivo source of tumor-antigen-specific killer T cells.

Opportunities

The Stem-to-T-Cell platform addresses key limitations of current CAR-T therapies, such as severe toxicity and limited durability, potentially opening the large solid tumor market to cell therapy.

The existing clinical-stage DC vaccine portfolio provides immediate partnership opportunities to generate non-dilutive funding and validate the company's scientific approach.

Risk Factors

The core Stem-to-T-Cell technology is at an early pre-clinical stage with unproven human efficacy and safety, representing high technical risk.

As a private, pre-revenue company, it faces significant financial risk and is dependent on raising capital in a competitive environment.

The immuno-oncology field is crowded with well-funded competitors advancing alternative next-generation therapies.

Competitive Landscape

PLSG competes in the broad cancer immunotherapy space, directly with developers of CAR-T, TCR-T, and dendritic cell vaccines. Its Stem-to-T-Cell approach is a novel competitor to allogeneic 'off-the-shelf' cell therapies and next-gen autologous CAR-Ts aiming for improved safety profiles. Success requires demonstrating clear differentiation in manufacturing, persistence, and toxicity compared to these established modalities.

More companies in Cell & Gene Therapy →More companies in United States →